National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedChu DK, Abrams EM, Golden BK
Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis.
The purpose of this systematic review and meta-analysis of case studies and case reports was to assess the risk of severe immediate allergic reactions to a second dose of SARS-CoV-2 mRNA vaccine in people who experienced an immediate allergic reaction to the first dose. The researchers evaluated the World Health Organization Global Coronavirus database, Web of Science, MEDLINE, and Embase from the date of inception through October 4th, 2021. The main outcomes and measures were a risk of severe immediate allergic reaction and repeated severe immediate allergic reactions with a second vaccine dose. The study found that among 22 studies of SARS-CoV-2 mRNA vaccines, 1366 individuals had immediate allergic reactions to their first vaccination. Of these, 87.8% were women with a mean age of 46.1 years. Six patients developed severe immediate allergic reactions after their second vaccination, 232 developed mild symptoms, and 1360 tolerated the dose. Among 78 persons with severe immediate allergic reactions to their first SARS-CoV-2 mRNA vaccination, 4 people had a second severe immediate reaction, and 15 had non-severe symptoms. There were no deaths. The study concluded that in a supervised setting equipped to manage severe allergic reactions, revaccination of individuals with an immediate allergic reaction to a first SARS-CoV-2 mRNA vaccine dose can be safe.
AHRQ-funded; HS026395.
Citation: Chu DK, Abrams EM, Golden BK .
Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis.
JAMA Intern Med 2022 Apr;182(4):376-85. doi: 10.1001/jamainternmed.2021.8515..
Keywords: COVID-19, Vaccination, Risk, Evidence-Based Practice, Patient-Centered Outcomes Research
Bergman ZR, Usher M, Olson A
Comparison of outcomes and process of care for patients treated at hospitals dedicated for COVID-19 care vs other hospitals.
The purpose of this study was to analyze the mortality rate and complications associated with treatment at the COVID-19-dedicated hospitals. Findings showed that, in this cohort study, COVID-19-dedicated hospitals in Minnesota had multiple benefits, including providing high-volume repetitive treatment and isolating patients with the infection. This experience suggests improved in-hospital mortality for patients treated at dedicated hospitals.
AHRQ-funded; HS026732; HS026379.
Citation: Bergman ZR, Usher M, Olson A .
Comparison of outcomes and process of care for patients treated at hospitals dedicated for COVID-19 care vs other hospitals.
JAMA Netw Open 2022 Mar;5(3):e220873. doi: 10.1001/jamanetworkopen.2022.0873..
Keywords: COVID-19, Patient-Centered Outcomes Research, Evidence-Based Practice, Outcomes, Healthcare Delivery, Hospitals
Bhalala US, Gist KM, Tripathi S
Characterization and outcomes of hospitalized children with coronavirus disease 2019: a report from a multicenter, viral infection and respiratory illness universal study (Coronavirus Disease 2019) registry.
The purpose of this retrospective study was to examine data from the Society of Critical Care Medicine Viral Infection and Respiratory Illness Universal Study (Coronavirus Disease 2019) registry and describe the characteristics, ICU admissions, and outcomes in children hospitalized with COVID-19. The study included 874 children under the age of 18 hospitalized with coronavirus disease 2019 at 51 participating hospital centers from February 2020 to January 2021. The primary outcome was ICU admission. Secondary outcomes included hospital and ICU duration of stay and ICU, hospital, and 28-day mortality. The researchers found that the median age was 8 years, with 62.9% non-Hispanic and a boy to girl ratio of 1:2. A total of 28.2% of the children met the Centers for Disease Control and Prevention criteria for multisystem inflammatory syndrome in children, and 46.2% were admitted to the ICU. A child’s age, the presence of a fever, multisystem inflammatory syndrome, and pre-existing seizure disorder were independently associated with a greater odds of ICU admission. The rate of hospital mortality for this group was 1.8%. The median duration of ICU stay was 3.9 days and the median duration of hospital stay was 4 days. For those patients with 28-day data, the survival rate was 86.3%. The researchers concluded that in this study, older age, fever, multisystem inflammatory syndrome in children, and seizure disorder were independently related with ICU admission.
AHRQ-funded; HS026393; HS026485.
Citation: Bhalala US, Gist KM, Tripathi S .
Characterization and outcomes of hospitalized children with coronavirus disease 2019: a report from a multicenter, viral infection and respiratory illness universal study (Coronavirus Disease 2019) registry.
Crit Care Med 2022 Jan;50(1):e40-e51. doi: 10.1097/ccm.0000000000005232..
Keywords: COVID-19, Children/Adolescents, Registries, Patient-Centered Outcomes Research, Evidence-Based Practice, Inpatient Care